The HMG-CoA reductase inhibitor, pravastatin, prevents the development of monocrotaline-induced pulmonary hypertension in the rat through reduction of endothelial cell apoptosis and overexpression of eNOS

By Guerard Pascal   Rakotoniaina Zo   Goirand Françoise   Rochette Luc   Dumas Monique   Lirussi Frederic   Bardou Marc  

Naunyn-Schmiedeberg's Archives of Pharmacology, Vol. 373, Iss. 6, 2006-09 ,pp. : 401-414

Springer Publishing Company

Access to resources Recommend Favorite

Pluripotential Mechanisms of Cardioprotection with HMG-CoA Reductase Inhibitor Therapy

By Rosenson R.S.  

American Journal of Cardiovascular Drugs, Vol. 1, Iss. 6, 2001-06 ,pp. : 411-420

Adis International

Access to resources Recommend Favorite

NK-104: a novel synthetic HMG-CoA reductase inhibitor

By Kajinami K.   Mabuchi H.   Saito Y.  

Expert Opinion on Investigational Drugs, Vol. 9, Iss. 11, 2000-11 ,pp. : 2653-2661

Informa Healthcare

Access to resources Recommend Favorite

HMG-CoA reductase inhibitors: First report of decreased libido with atorvastatin, fluvastatin, pravastatin and simvastatin: 8 case reports

By  

Reactions Weekly, Vol. 1, Iss. 1039, 2005-01 ,pp. : 9-9

Adis International

Access to resources Recommend Favorite

The protective effect of HMG-CoA reductase inhibitors against monocrotaline-induced pulmonary hypertension in the rat might not be a class effect: comparison of pravastatin and atorvastatin

By Rakotoniaina Zo   Guerard Pascal   Lirussi Frederic   Goirand Françoise   Rochette Luc   Dumas Monique   Bardou Marc  

Naunyn-Schmiedeberg's Archives of Pharmacology, Vol. 374, Iss. 3, 2006-12 ,pp. : 195-206

Springer Publishing Company

Access to resources Recommend Favorite